ELI LILLY & CO
LLYNYSETrading Snapshot
- Day Range
- $1,157.28 – $1,184.72
- 52-Week Range
- $725.31 – $1,292.65
- Volume
- $15.27B
- Avg Volume
- $12.18B
- Shares Outstanding
- 941.7M
- Next Earnings
- Nov 23, 2026
Fundamentals Snapshot
- Annual Revenue
- $65.18B
- Last Q Revenue
- $22.97B
- P/E Ratio
- 39.2
- P/S Ratio
- 13.9x
- EPS (TTM)
- $29.93
- Dividend Yield
- 0.57%
- Dilution (1yr)
- −0.6%
Why Investors Own LLY
- ✓High-growth profile — revenue up -1.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 53% gross margin and 21% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ELI LILLY & CO
LLY
StockOtter · stockotter.spaceAbout ELI LILLY & CO
Pharma with leading GLP-1 franchise (Mounjaro, Zepbound).
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Wall Street Breakfast Podcast: Federal Boost For Navitas
Navitas Semiconductor (NVTS) surged 12% premarket after winning a U.S. Army contract to develop next-gen silicon carbide power semiconductor technology. Eli Lilly (LLY) signals intent for larger, earlier-stage acquisitio
Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison
Foundayo 17.2 mg was associated with 1.5% greater weight loss and 0.3% greater A1C reduction than oral semaglutide 25 mg at 52 weeks These additional analyses build on findings of the ACHIEVE-3 head-to-head study, where
LLY's Olumiant Gets FDA Nod for Expanded Use in Pediatric Hair Loss
Eli Lilly's Olumiant wins FDA nod to treat pediatric patients 12 years of age and older with severe alopecia areata, expanding its U.S. use after strong phase III results.
Eli Lilly (LLY) is a Top-Ranked Momentum Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
He Will Switch Contractors to Help Build Eli Lilly’s $6.5 Billion Plant. Two W-2s Could Put $2,821 in Social Security Taxes Back in His Pocket
A pipefitter switching contractors during construction of a massive new pharmaceutical plant could walk away from tax season with a surprise windfall, and most workers in the same situation never even realize the money e